Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers
On March 10, 2021, CorMedix Inc. (the “Company”
or “we”) entered into an employment agreement with Elizabeth Masson-Hurlburt, our Executive Vice President and Head
of Clinical Operations. After the initial three-year term of the employment agreement, the agreement will automatically renew for
additional successive one-year periods, unless either party notifies the other in writing at least 90 days before the expiration
of the then current term that the agreement will not be renewed. The employment agreement is similar to and replaces the prior
agreement with Ms. Masson-Hurlburt that we entered into in March 2018 and which had a term of three years.
Pursuant to the agreement, Ms. Masson-Hurlburt
will receive an annual salary of $315,000, which cannot be decreased unless all officers and/or members of our executive management
team experience an equal or greater percentage reduction in base salary and/or total compensation, provided that any reduction
in Ms. Masson-Hurlburt’s salary may be no greater than 25%. Ms. Masson-Hurlburt will be eligible for an annual bonus, which
may equal up to 30% of her base salary then in effect, as determined by our Board of Directors or the Compensation Committee thereof.
In determining such bonus, our Board or the Compensation Committee will take into consideration the achievement of specified company
objectives, established by the Board or the Compensation Committee, and such other factors as the Board or the Compensation Committee
deems appropriate. Ms. Masson-Hurlburt must be employed through December 31 of a given year to be eligible to earn that year’s
annual bonus.
Each year during the term, we will make
an annual equity grant to Ms. Masson-Hurlburt, which may include restricted stock, restricted stock units or stock options, with
time-based or performance-based vesting, in such amounts and on such terms as the Board or the Compensation Committee deems appropriate.
If we terminate Ms. Masson-Hurlburt’s
employment for Cause (as defined below), she will be entitled to receive only the accrued compensation due to her as of the date
of such termination, rights to indemnification and directors’ and officers’ liability insurance, and as otherwise required
by law. All unvested equity awards and all unvested stock options then held by Ms. Masson-Hurlburt that were granted before the
effective date of her employment agreement will be forfeited to us as of such date. All outstanding equity awards and all outstanding
stock options then held by Ms. Masson-Hurlburt that are granted on or after the effective date of her employment agreement, whether
or not vested, will be forfeited to us as of such date.
If we terminate Ms. Masson-Hurlburt’s
employment other than for Cause, death, disability, or by notice of nonrenewal, or if she resigns for Good Reason (as defined below),
including in each case within 24 months of a Corporate Transaction (as defined in the agreement and which is the same definition
as in our 2019 Omnibus Stock Incentive Plan), Ms. Masson-Hurlburt will receive the following benefits: (i) payment of any accrued
compensation and any unpaid bonus for the prior year, as well as rights to indemnification and directors’ and officers’
liability insurance and any rights or privilege otherwise required by law; (ii) payment of her base salary for a period of 9 months
following the effective date of the termination of employment; (iii) payment on a prorated basis for any target bonus for the year
of termination based on the actual achievement of the specified bonus objectives; (iv) if she timely elects continued health insurance
coverage under COBRA, payment of the premium to continue such coverage for her and her eligible dependents in an amount equal to
the portion paid for by us during her employment until the conclusion of the time when she is receiving continuation of base salary
payments or until she becomes eligible for group health insurance coverage under another employer’s plan, whichever occurs
first; (v) except as provided in (vii) below, all equity awards and stock options that are scheduled to vest on or before the next
succeeding anniversary of the date of termination shall be accelerated and deemed to have vested as of the termination date, provided
that any performance-based equity awards and stock options whose vesting requirements have not been successfully met as of the
date of termination will not accelerate; (vi) except as provided in (vii) below, vested stock options will be exercisable for 90
days following termination of employment or, if earlier, the expiration date of the stock option, and (vii) in the event of a Corporate
Transaction, all equity awards and stock options shall become fully vested and exercisable, and the stock options will remain exercisable
for 12 months following such termination or resignation or, if earlier, the expiration date of the stock option. The separation
benefits set forth above are conditioned upon Ms. Masson-Hurlburt’s executing a release of claims against us, our parents,
subsidiaries, and affiliates, and each such entities’ officers, directors, employees, agents, successors, and assigns in
a form acceptable to us, within a time specified therein, which release is not revoked within any time period allowed for revocation
under applicable law.
For purposes of the agreement, “Cause”
is defined as: (i) the willful failure, disregard, or refusal by Ms. Masson-Hurlburt to perform her material duties or obligations
under the agreement (other than as a result of her mental incapacity or illness, as confirmed by medical evidence provided by a
physician selected by us); (ii) any willful, intentional, or grossly negligent act by Ms. Masson-Hurlburt having the effect of
materially injuring (whether financially or otherwise) our business or reputation or any of our affiliates; (iii) Ms. Masson-Hurlburt’s
conviction of any felony involving moral turpitude (including entry of a guilty or nolo contendere plea); (iv) Ms. Masson-Hurlburt’s
qualification as a “bad actor,” as defined by 17 CFR 230.506(a); (v) the good faith determination by the Board, after
a reasonable and good-faith investigation by us that Ms. Masson-Hurlburt engaged in some form of harassment or discrimination prohibited
by law (including, without limitation, harassment on the basis of age, sex or race) unless her actions were specifically directed
by the Board; (vi) any material misappropriation or embezzlement by Ms. Masson-Hurlburt of our or our affiliates’ property
(whether or not a misdemeanor or felony); or (vii) material breach by Ms. Masson-Hurlburt of the agreement that is not cured, to
the extent subject to cure, by her to our reasonable satisfaction within 20 days after we give written notice thereof to her.
For purposes of the agreement,
“Good Reason” is defined as: (i) any material breach of the agreement by us; (ii) any material diminution by us
of Ms. Masson-Hurlburt’s duties, responsibilities, or authority; or (iii) a material reduction in Ms.
Masson-Hurlburt’s annual base salary unless all officers and/or members of our executive management team experience an
equal or greater percentage reduction in annual base salary and/or total compensation and any reduction in Ms.
Masson-Hurlburt’s salary and/or total compensation is no greater than 25%; or (v) a material reduction in Ms.
Masson-Hurlburt’s target bonus level unless all officers and/or members of our executive management team experience an
equal or greater percentage reduction related to target bonus levels and Ms. Masson-Hurlburt’s target bonus level
reduction is no greater than 25%.
If Ms. Masson-Hurlburt terminates her employment
by written notice of termination or if she or we terminate her employment by providing a notice of nonrenewal at least 90 days
before the agreement is set to expire, Ms. Masson-Hurlburt will not be entitled to receive any payments or benefits other than
any accrued compensation, any unpaid prior year’s bonus, rights to indemnification and directors’ and officers’
liability insurance, and as otherwise required by law.
If Ms. Masson-Hurlburt’s employment
is terminated as a result of her death or disability, we will pay her or her estate, as applicable, any accrued compensation and
any unpaid prior year’s bonus.
Our agreement with Ms. Masson-Hurlburt
contains a non-compete provision that provides that during the term of the agreement and the 12-month period immediately
following Ms. Masson-Hurlburt’s separation from employment for any reason, Ms. Masson-Hurlburt is prohibited from
engaging in any business involving the development or commercialization of a preventive anti-infective product that would be
a direct competitor of Neutrolin or a product containing taurolidine or any other product being actively developed or
produced by us anywhere in the world on the date of termination of her employment.
The employment agreement is filed as Exhibit
10.1 to this Current Report on Form 8-K and is incorporated herein by reference. The foregoing description of the employment agreement
is not complete and is qualified in its entirety by reference to Exhibit 10.1.